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oligoprogression or dominant tumour/local control. LC is highest 
for lung tumours which received the highest SBRT doses. 
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Purpose: Primary hepatocellular (HCC) and secondary liver 
metastases (METS) is a growing problem. Despite the increasing 
use of liver stereotactic body radiotherapy (SBRT), there is a lack 
of a predictive model to understand which patients benefit from 
treatment. This study developed a model to improve patient 
selection for radical radiotherapy for liver malignancies.  
Methods and Materials: Two hundred and twelve (HCC (31%), 
METS (69%)) patients were identified. We excluded those 
receiving low dose palliative radiation. Patients dying within four 
months were deemed to have failed to benefit from radiation. 
Both patient and tumour parameters were selected for 
univariate analysis. Patient factors included age, sex and liver 
function (Child-Pugh (CP) score, serum albumin (ALB), total 
bilirubin, prothrombin time, presence of ascites). Tumour 
factors included gross tumour volume (GTV), number of lesions, 
presence of extrahepatic disease (ED), previous treatments 
(resection, chemotherapy, chemoembolization) and primary 
disease site if metastatic. Multivariable regression analysis was 
used to develop a clinical predictive tool.  
Results: For HCC, CP score and a larger GTV were found to be 
significant predictors of early death. For the METS group, ALB, 
presence of ED and colorectal primary were significant 
predictors. For the combined set, CP score (HR = 0.7), ALB (HR = 
1.1), previous resection (HR = 5.2) and presence of ED (HR = 0.4) 
were significant predictors. Chi-squared analysis showed a 
significant (p < 0.01) reduction in deviance indicating that the 
model has good predictive value. ANOVA indicated that while 
each variable significantly reduced the residual deviance, the 
model is not saturated.  
Conclusions: A model was developed to identify patients who 
are unlikely to benefit from radiation. The model is not saturated 
and additional variables need to be identified. Multi-institutional 
collaboration is required to obtain a larger sample size, as single 
centres are unlikely to obtain sufficient numbers for this disease 
site. Until then, all patients meeting commonly accepted liver 
SBRT eligibility should be offered radiation. 
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Purpose: Head and neck basal cell carcinoma (HN-BCC) is mainly 
managed by primary surgery. Radiotherapy (RT) is sometimes 
used for aggressive form BCC with adverse pathological features 
or occasionally as a definitive treatment alternative to surgery 
to enhance locoregional control (LRC). This study reviews 
outcome of HN-BCC following mega-voltage RT in our institution. 
Methods and Materials: All HN-BCC received definitive or post- 
operative RT (PORT) between 1998 and 2014 were reviewed. 
Physician reported cosmetic outcome were recorded as a binary 
valuable (“good” or “poor”). Locoregional control (LRC), 
recurrence-free survival (RFS), and overall survival (OS) were 
calculated for all cases and for cases receiving definitive RT. 
Univariate analysis (UVA) assessed the association of tumour 
factors and LRC. 
Results: A total of 111 consecutive HN-BCC were identified 
including 71 newly diagnosed and 40 recurrent BCC (rBCC). 
Median age was 76 years. All cases were aggressive form BCC 
with initial diameter > 1 cm (n = 109) patients, > 2 recurrence (n 
= 24) or extra-cutaneous extension (n = 30). Definitive RT (45-70 
Gy at 1.8-4.5 Gy per fraction) was given in 73 (65.7%) cases for 
the following reasons: technically not suited for surgery (n = 20), 
cosmetic consideration (n = 42), and high operation risk due to 
age or comorbidities (n = 11). PORT (50-66 Gy at 1.8-2 Gy per 
fraction) was given in 38 cases for either adverse pathological 
features (compromised margins, deep invasion, and positive 
lymph nodes) (n = 26/38) or history of multiple recurrences (n = 
14/38). Chemotherapy was only used in six (5.4%) patients in 
adjuvant setting. Median follow up was 4.7 years. Five-year LRC, 
RFS, and OS were 87%, 82%, and 93% for the entire cohort and 
85%, 82%, and 96% for definitive RT subset. UVA revealed that 
rBCC [hazard ratio (HR) 8.03 (95% CI: 1.04-61.9), p = 0.04], 
primary arising from peri-orbital/peri-auricular region [HR 0.03 
(1.06-9.13), p = 0.05], tumour size [HR 1.32 (1.08-1.61), p < 
0.01], lymph node involvement (N+) [HR 3.7 (1.11-12.3), p = 
0.03] and Stage III/IV [HR 3.16 (1.19-8.36), p = 0.03] were 
associated with increased risk of locoregional recurrence. 
Tumour size [HR 1.23 (1.02-1.47), p = 0.02] and N+ [HR 4.84 
(1.57-14.95), p < 0.01] had a significant poor OS. Physician 
reported cosmetic outcome were good in 70/82 (85%) patients. 
Conclusions: This study shows that RT is a valid alternative 
option for HN-BCC with a high LRC when used as single modality 
or in PORT setting with good overall cosmetic outcome. 
Recurrent tumour, size, nodal involvement and stage are 
associated with increased risk of recurrence. 
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Purpose: The Phoenix definition of biochemical failure (BF) 
(nadir+2) may overestimate cure rates after low dose rate 
prostate brachytherapy (LDR-PB). The purpose of this study is to 
assess long-term PSA stability after LDR-PB and predictive factors 
of eventual BF for those with a slowly rising PSA. 
Methods and Materials: 2772 low or intermediate-risk prostate 
cancers underwent Iodine-125 LDR-PB monotherapy between 
1998 and 2010. 49.7% received androgen deprivation (ADT) prior 
to LDR-PB (treatment policy: six months). Patients with less than 
36 months follow up were excluded (n = 433). Clinical 
characteristics, dosimetric parameters and sequential PSA 
readings were retrieved from a prospective provincial database. 
A rising PSA was considered to be PSA ≥ 0.2 ng/mL with an 
increase ≥ 0.1 ng/mL over previous two years. The Phoenix 
definition was used to identify BF. Patients were classified as: 1) 
stable PSA (cured); 2) rising PSA (without BF); or 3) BF. The three 
groups were compared according to clinical, dosimetric and post-
treatment parameters. Multivariate analysis was performed on 
the cured and failed groups to determine variables predicting for 
failure. Logistic regression model was applied with cross 
validation to test for model accuracy. ROC curves were obtained 
for patients with and without ADT to determine predictive cut-
offs for BF. 
Results: Median follow up is 89 months (37-199); median age at 
implant 66 years (43-84). Majority of patients (80.7%) had clinical 
Stage T1-T2a, 55% had Gleason score ≤ 6 and median baseline 
PSA was 6.5 ng/mL(0.3-40 ng/mL). 59% were intermediate-risk. 
Among the 2339 patients analyzed, 2004 (85.7%) had a stable PSA 
and were considered cured [median PSA at 60 months (PSA-60): 
0.04ng/mL], 145 (6.2%) had a rising PSA (PSA-60: 0.27 ng/mL) 
and 190 (8.1%) had BF. PSA nadirs for the three groups were 
respectively 0.03 (cured), 0.16 (rising PSA) and 0.51 ng/mL (BF) 
(p < 0.0001). For patients with no prior ADT, the variables 
associated with failure are PSA nadir (OR: 20.6 p < 0.0001) and 
PSA-60 (OR: 18.3 p < 0.0001). If the model is applied to the rising 
PSA group, using a PSA-60 cut-off of 0.3 ng/mL (sensitivity: 85%, 
